RP-A501
RP-A501-0123
Phase 2 gene_therapy active
Quick answer
RP-A501 for Danon Disease is a Phase 2 program (gene_therapy) at Rocket Pharmaceuticals B.V. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Rocket Pharmaceuticals B.V.
- Indication
- Danon Disease
- Phase
- Phase 2
- Modality
- gene_therapy
- Status
- active